Search NLS News

Orion Corporation has signed a long-term license agreement with Amneal Pharmaceuticals to commercialize Amneal’s generic products in Orion territories. Under the terms of the agreement, Orion is granted exclusive licence to commercialize and sell Amneal’s generic products in most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include […]

We would like to thank our readers, subscribers and collaboration partners for a fruitful 2022, and we wish you all a most wonderful holiday season! 2022 has been – yet another – challenging year and we have reported about how it is to work from Ukraine and how our industry is affected by the uncertain […]

The emergence of new technologies at the forefront of new drug development, for example gene therapy, is driving a demand for tailor-made solutions and cutting-edge expertise throughout the biopharma industry. An increasing demand for needs-adapted molecular therapeutics is placing high demands on suppliers, and, not least, on suppliers of purification solutions. Customers want tailor-made chromatography […]

In today’s financial climate, companies should boost their international position by leveraging the strengths that are inherent to the region’s life science eco system and to the Nordic work culture in general. The air was practically buzzing with energy at Nordic Life Science Days 2022 (NLSDays) in Malmö, in September. The appetite for meeting in […]

Swedish Anocca has secured Venture Debt financing from the European Investment Bank (EIB). This significant investment recognizes the strength and high potential of Anocca and its transformational approach to developing T-cell therapies for cancer, the company states. “This financing supports us in moving our first generation of T-cell immunotherapies towards clinical trials in a solid […]

AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the European Union as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca and Daiichi […]

Ultimovacs has announced that cemiplimab (Libtayo) will be used as the PD-1 checkpoint inhibitor in combination with UV1 in the Phase II randomized LUNGVAC trial rather than pembrolizumab (Keytruda). The move, which will be implemented January 1, 2023, follows the decision by the Norwegian Health Authorities of reimbursement of cemiplimab for monotherapy or first-line treatment […]

An old train station area just north of the Stockholm city center is being developed into a unique ecosystem for life science researchers and businesses. The new city neighborhood of Hagastaden, due to be finalized 2030, extends the inner city of Stockholm and integrates Stockholm with Solna. The 96 hectare-large area spans all the way […]

Nykode Therapeutics has entered into a strategic manufacturing partnership with Richter-Helm BioLogics to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “We are excited about the strategic manufacturing partnership with Richter-Helm BioLogics. As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity needed to support our ambitious […]

The Science4Peace Summit, a manifestation of the Swedish American Life Science Summit (SALSS) together with The Galien Foundation, took place in Stockholm on the 12th of December during the Nobel festivities. Barbro Ehnbom, the founder of SALSS, and her team had invited dignitaries in science, life science and healthcare to participate in a manifestation for […]